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Abstract
Purpose Fusion dual-tracer SPECT imaging enables physio-
logical rather than morphological voxel-based partitioning
and dosimetry for 90Y hepatic radioembolization (RE). We
evaluated its prognostic value in a large heterogeneous cohort
of patients with extensive hepatic malignancy.
Methods A total of 122 patients with primary or secondary
liver malignancy (18 different cell types) underwent SPECT
imaging after intraarterial injection of 99mTc macroaggregated
albumin (TcMAA) as a simulation of subsequent 90Y micro-
sphere distribution, followed by administration of an excess of
intravenous 99mTc-labelled sulphur colloid (TcSC) as a bio-
marker for functional liver, and a second SPECT scan.
TcMAA distribution was used to estimate 90Y radiation
absorbed dose in tumour (DT) and in functional liver.
Laboratory and clinical follow-up were recorded for
12 weeks after RE, and radiographic responses accord-
ing to (m)RECIST were evaluated at 3 and 6 months.
Dose–response relationships were determined for effica-
cy and toxicity.
Results Patients were treated with a median of 1.73 GBq ac-
tivity of resin microspheres (98 patients) or glass microspheres
(24 patients), in a whole-liver approach (97 patients) or a lobar
approach (25 patients). The objective response rate was 41 %
at 3 months and 48 % at 6 months. Response was correlated
with DT (P<0.01). Median overall survival was 10.1 months
(95 % confidence interval 7.4 – 12.8 months). Responders
lived for 36.0 months compared to 8.7 months for nonre-
sponders (P<0.01). Stratified for tumour cell type, DT was
independently associated with survival (P<0.01). Absorbed
dose in functional liver was correlated with toxicity grade
change (P<0.05) and RE-induced liver disease (P<0.05).
Conclusion Fusion dual-tracer SPECT imaging offers a
physiology-based functional imaging tool to predict efficacy
and toxicity of RE. This technique can be refined to define
dosing thresholds for specific tumour types and treatments,
but appears generally predictive even in a heterogeneous
cohort.
Keywords Radioembolization . Treatment planning .
Functional imaging . Partitionmodel . SPECT
Introduction
Treatment planning is critical to the success of 90Y hepatic
radioembolization (RE) [1]. Safety and efficacy are contingent
upon inhomogeneous intrahepatic distribution of radioactive
microspheres to achieve tumoricidal doses without serious
hepatic injury. Current standard methods for activity calcula-
tion for both resin and glass microspheres were largely vali-
dated on empirical grounds [2–8]. Although these early dose
ranging studies were sufficient to show promising results and
an acceptable toxicity profile, imperfect response rates and
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occasional severe toxicities continue to drive investigators to-
wards optimization of RE treatment planning [9].
Recent proposals to improve treatment planning are based
on morphological partition modelling using CT or MRI to
delineate the anatomical borders of tumours within the liver
volume, combined with SPECT imaging to calculate the ac-
tivity distribution within these target volumes [10, 11]. These
methods incorporate dosimetric parameters such as tumour
and normal liver absorbed doses in the activity calculations,
and seem to be feasible and accurate in patients with a limited
number of clearly demarcated tumours, mostly hepatocellular
carcinomas (HCC) [12]. However, in the presence of diffuse,
infiltrative HCC or myriad heterogeneous metastases, ana-
tomical partition modelling is prone to significant error [1].
These partition methods are therefore difficult to standardize
in clinical practice.
We proposed a new partition method using physiological
parameters only: a segmentation tool based on a dual-tracer
SPECT technique, combining 99mTc macroaggregated albu-
min (TcMAA) SPECT for simulation of 90Y activity distribu-
tion, and 99mTc-sulphur colloid (TcSC) SPECT for identifying
functional liver parenchyma [13]. This method obviates the
need to delineate the different compartments by anatomical
imaging and is automated, fast, and objective. In a homoge-
neous cohort of 25 patients with metastatic colorectal carcino-
ma (mCRC), we found that the calculated absorbed doses to
the tumour compartment (DT) and to the functional liver com-
partment (DFL-TOT) are significantly correlated with efficacy
and toxicity. In the present study, we broadened validation to a
large heterogeneous cohort of patients with many different




Between June 2004 and September 2011, 247 consecutive
patients underwent intraarterial TcMAA imaging as part of
their RE preparatory work-up. Of these, 184 underwent intra-
venous TcSC imaging. In 38 patients, mismatch in injection
positions of TcMAA and 90Y jeopardized the accuracy of
distribution simulation and these patients were excluded. In
addition, 24 patients who received treatment in two staged
sessions were excluded because pretreatment TcMAA was
injected nonstaged and nonselectively. A total of 122 patients
(68men, 54women;median age 62 years, range 25 – 92 years)
were included in the analysis, including 25 previously studied
patients [13]. Baseline, procedural, and follow-up data were
collected prospectively as standard of care, and retrospectively
analysed for this study. Data were handled in accordance with
the Health Insurance Portability and Accountability Act. The
institutional review board approved the study. Table 1 sum-
marizes the patient characteristics.
Radioembolization
Activity calculations and treatments were performed accord-
ing to international consensus guidelines [14–16]. Resin mi-
crospheres (SIR-Spheres; SIRTex Medical Ltd., North Syd-
ney, Australia) were used to treat 98 patients (80.3 %). The
prescribed activity was calculated based on body surface area
(BSA) and estimated tumour liver involvement (LI; median
25 %, range 5–70 %), where prescribed activity (GBq)=BSA
(m2) − 0.2+LI [12]. Glass microspheres (TheraSphere; BTG,
Inc., Farnham, UK) were used to treat 24 patients, applying a
medical internal radiation dosimetry (MIRD) method to pre-
scribe a desired target territory absorbed dose of 90 – 120 Gy
[17]. Hepatopulmonary shunting was compensated for by the
recommended activity adjustments [17, 12].
Clinical and laboratory follow-up were performed 2, 4, 8 and
12 weeks after treatment, and at intervals prescribed by the med-
ical oncologist thereafter. Toxicity was graded according to
National Cancer Institute common toxicity criteria for adverse
events (NCI-CTCAE v4.03). Follow-up imaging replicating the
pretreatment modality was used for response analysis according
to modified Response Evaluation Criteria in Solid Tumors
(mRECIST) [18] for HCC and RECIST 1.1 for other tumour
types, with a focus on liver response only [19]. One blinded
reviewer performed over-reads of all clinical interpretations.
Imaging procedures
As described previously [13], routine SPECT was performed
after intraarterial administration of a small TcMAA dose
(37 MBq). Without moving the patient, an excess of TcSC
(185 MBq) was administered intravenously, and SPECT was
repeated after a 5-min delay. SPECT data were acquired on a
dual-head Infinia Hawkeye 4 gamma camera (GE Healthcare,
Waukesha, WI), with a 64 × 64 matrix (voxel size
0.884 mm3), 130–150 keV energy window, low-energy
high-resolution collimator and 120 projections (15 s per pro-
jection) over a 360° full circular orbit.
Image processing and analysis
Data were reconstructed using filtered back projection and a
Butterworth postreconstruction filter (Fc 0.23; order 6), using
Segami software (Segami, Columbia, MD). From the TcMAA
SPECT images (Fig. 1a), a three-dimensional tumour map
(Fig. 1b) was generated by applying a threshold including
all voxels with 10 % or more of the maximum TcMAA per
voxel, using software programmed in IDL 6.1 (Exelis, Inc.,
McLean, VA). This threshold was chosen after comparison
between 5–30 %. Corrected TcSC images (Fig. 1c) were then
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calculated by subtracting TcMAA images (Fig. 1a) from the
TcSC images. A map of functional liver (Fig. 1d) was pro-
duced by applying a 10 % threshold to the corrected TcSC
images. Fusing the TcMAA and TcSC maps (Fig. 1e) resulted
in hepatic segmentation into four compartments: (1) the
unirradiated functional liver compartment (VFL-UN, TcSC-
positive only; Fig. 1f); (2) the tumour compartment (VT,
TcMAA-positive only; Fig. 1g); (3) the overlap area, the irra-
diated functional liver compartment (VFL-IR, both TcSC- and
TcMAA-positive; Fig. 1h) which typically represented the
Table 1 Demographics, baseline
characteristics and oncological
histories of the cohort
Characteristic Value
Sex (male/female), n 68/54
Age (years), median (range) 62 (25–92)
Tumour cell type, n (%)
Hepatocellular carcinoma 26 (21.3)
Cholangiocarcinoma 18 (14.7)
Metastatic neuroendocrine carcinoma 20 (16.4)
Metastatic colorectal carcinoma 29 (23.8)
Othera 29 (23.8)
Previous systemic treatment, n (%)
Cytotoxic chemotherapy 74 (60.7)
Bevacizumab 36 (29.5)
Sorafenib 12 (9.8)
Anti-EGFR agents 18 (14.8)
Previous liver-directed treatment, n (%)
Transarterial (chemo)embolization 27 (22.1)
Partial liver resection 26 (21.3)
Radiofrequency ablation 18 (14.8)
External beam radiation therapyb 8 (6.6)
Hepatic radioembolization 7 (5.7)




Extrahepatic disease, n (%) 61 (50)
Lung 37 (30.3)
Lymph nodes 16 (13.1)
Bone 10 (8.2)
Estimated liver tumour involvement (%), median (range) 25 (5–70)
Maximum tumour diameter (mm), median (range) 52 (15–133)





Whole liver 97 (79.5)
Lobar 25 (20.5)
Administered activity (GBq), median (range) 1.73 (0.43–6.21)
EGFR epidermal growth factor receptor
a Includes sarcoma (five patients), melanoma (four), renal cell carcinoma (three), pancreatic adenocarcinoma
(three), oesophageal carcinoma (three), ovarian carcinoma (one), urothelial carcinoma (one), small-cell lung
carcinoma (one), lymphoma (one), cervical carcinoma (one), thymic carcinoma (two), breast carcinoma (two),
ampullary carcinoma (one), and gastronintestinal junction carcinoma (one)
b The mean radiation absorbed dose to the liver was determined by dose–volume histogram analysis. All mean
liver doses >1 Gy were included
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marginal zone that included hypervascular rims; and (4) the
null compartment (VNULL, both TcSC- and TcMAA-negative)
which included central necrosis, major vascular structures,
cysts, etc. The total functional liver compartment or VFL-TOT
was defined as VFL-IR plus VFL-UN, and the total liver volume
VTOTAL LIVER was calculated as VT plus VFL-TOT. The process
of fusion of the TcSC and TcMAA images to define the four
liver compartments is shown in Fig. 2.
Voxel counts were converted into volumes, and deposited
TcMAA activities were converted into compartment absorbed
doses using the MIRD formula [20]:
Compartment absorbed dose=(compartment TcMAA
activity/total TcMAA activity) × administered activity
(GBq) × 1.029−1 (kg/L) × volume−1 (L) × 50
where ‘compartment TcMAA activity’ is the measured
TcMAA activity in a compartment, ‘total TcMAA activity’ is
the total TcMAA activity in the liver, 1.029 kg/L is the estimat-
ed specific density of hepatic tissue, ‘volume’ is the calculated
volume of the compartment (using a 10 % threshold as de-
scribed above), and ‘50’ is the conversion factor for 90Y from
GBq/kg to Gy. Below the 10 % threshold, calculatedDFL-UN to
the unirradiated functional liver was simplified as zero. Calcu-
lated absorbed dose in the other three compartments (DT, DFL-
TOT, DFL-IR), volumes of each compartment (VT, VFL-TOT, VFL-
UN and VFL-IR), ratios between parameters, and fractional
volumes were evaluated for dose–response relationships with
regard to efficacy and toxicity (Supplementary Tables 1 and 2).
Statistical analysis
A commercial software package was used for statistical anal-
ysis (SPSS for Windows, version 19.0; SPSS Inc, Chicago,
IL). The normality of the distributions of continuous variables
was tested using the Kolmogorov-Smirnov test. Nonparamet-
ric tests were used to compare groups (chi-squared test for
categorical variables, Mann-Whitney or Kruskal-Wallis one-
Fig. 1 A threshold applied to the
TcMAA SPECT image (a)
defines the MAA-positive
volume (b), and to the 99mTc-
sulphur colloid (SC) SPECT (c)
defines the SC-positive volume
(d). Coregistration of the two
SPECT scans results in four
compartments: f unirradiated
functional liver (VFL-UN), MAA-
negative, SC-positive (blue), g
tumour (VT), MAA-positive SC-
negative (red), h irradiated
functional liver (VFL-IR), MAA-
positive SC-positive (purple), and
tumour necrosis (VNULL), MAA-
negative SC-negative (black)
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way ANOVA for continuous variables). Survival was evalu-
ated using Kaplan-Meier curves. Stratification was performed
for tumour cell type with the log rank test for comparison
pooled over the strata. Multivariate survival analysis was per-
formed with a Cox proportional hazards model using the con-
ditional step forward method (stepwise probability: entry
0.05, removal 0.10). A P value <0.05 was considered statisti-
cally significant.
Results
The 122 patients were treated with a median of 1.73 GBq resin
microspheres (98 patients) or glass microspheres (24 patients),
in a whole-liver distribution (97 microspheres) or lobar distri-
bution (25 microspheres; Table 1). The majority of patients
treated with glass microspheres had HCC (22 of 24 patients).
The median administered activity of glass microspheres was
3.37 GBq compared to 1.64 GBq for resin microspheres
(P<0.001). The median tumour absorbed dose (DT) in the
total cohort was 36.3 Gy, and the median functional liver
absorbed dose (DFL-TOT) was 29.7 Gy (Table 2). This was
correlated significantly with tumour cell type (P<0.001). Pa-
tients with HCC had amuch higher medianDT (109.7Gy) and
DFL-TOT (55.1 Gy) than those with other cell types, mostly
because treatment with higher activity of glass microspheres
resulted in higher DT (116 Gy versus 32.7 Gy; P<0.001) and
DFL-TOT (57.1 Gy versus 27.3 Gy; P<0.001). However, inde-
pendent of the type of microspheres used, HCC also had a
higherDT/DFL-TOT ratio (median 1.8; P=0.02; Table 2), prob-
ably reflecting hypervascularity and focal tumours.
Of the 122 patients, 74 were evaluable for response at
3 months (18 died before follow-up imaging, 5 had inadequate
baseline imaging, and 25 did not have adequate follow-up
imaging), and 44 were evaluable at 6 months (48 died, 2
inadequate baseline imaging, 28 inadequate follow-up imag-
ing). The objective response rates (complete plus partial re-
sponses) were 41 % at 3 months and 48 % at 6 months
(Table 3). Response at 3 months was correlated only with
DT in the univariate analysis (P=0.026) and the multivariate
analysis (P=0.004). Other significant dosimetry parameters
(Supplementary Table 1) were strongly interrelated and were
Fig. 2 Functional liver tissue
defined by TcSC SPECT images
in three orientations (axial,
sagittal, coronal, a–c), simulated
90Y distribution defined by
TcMAA SPECT images in three
orientations (d–f), and the
coregistered fused SPECT images
in three orientations (g–i),
resulting in the definition of four
different compartments: tumour
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thus excluded. At 6 months, only a trend was found for DT in
the univariate analysis (P=0.069). At 3 months, responders
had a medianDTof 60.1 Gy versus 32.7 Gy for nonresponders
(P=0.026), and at 6 months 60.5 Gy versus 29.3 Gy (P=
0.069). The median survival (from treatment) in responders
at 3 months was 36.0 months, and in nonresponders was
8.7 months (P=0.003; stratified according to tumour cell type:
P=0.011; Fig. 3).
The overall median survival from treatment was
10.1 months (95 % confidence interval 7.4 – 12.8 months),
and from diagnosis 37.7 months (95 % confidence in-
terval 31.1 – 44.3 months; Table 3). At the time of
writing 34 patients were still alive with a median
follow-up of 27.1 months. Survival from treatment
(P<0.001) and survival from diagnosis (P<0.001) were
dependent on tumour cell type (Fig. 4). Patients with
HCC were selected for treatment with RE rather than
chemoembolization if they had very large tumours
(>8 cm), infiltrative disease, macrovascular invasion,
and/or had failed prior chemoembolization (Table 2),
resulting in expected poor overall survival after treat-
ment (Table 3). Of 26 HCC patients for example, 22
had underlying liver cirrhosis with significantly worse
liver function, and 5 had main portal vein thrombosis.
Stratified according to tumour cell type, DT was correlated
with survival after treatment in the univariate analysis (P=
0.004) and multivariate analysis (P=0.004). Only response,
tumour cell type, and DT were correlated with survival.
Table 2 Treatment parameters











26 56 109.7 55.1
Cholangiocarcinoma 18 76 35 24.9
Neuroendocrine
carcinoma
20 56 24.2 23.7
Colorectal carcinoma 29 46 33.3 27.8
Othera 29 44 33.6 29.8
All tumour types 122 52 36.3 29.7
P values (between
groups)b
NA 0.471 <0.001 <0.001
Variables are reported as medians
a Tumour cell types in this group are listed in Table 1 footnote a
bNonparametric Kruskal-Wallis one-way ANOVA for multiple pairwise comparison
Table 3 Treatment outcome according to tumour cell type
Tumour cell type Survival (months), median (95 % confidence
interval)
Response, n (%)a Grade 3 or 4 toxicity, n (%) REILD
From treatment From diagnosis At 3 months At 6 months
Hepatocellular carcinoma 8 (2.4–13.6) 32.4 (24.9–44) 9/15 (60) 7/10 (70) 10/22 (46) 2
Cholangiocarcinoma 5.7 (2.0–9.4) 21 (12.6–29.4) 2/11 (18) 2/5 (40) 2/16 (13) 1
Neuroendocrine carcinoma Not reached Not reached 8/14 (57) 6/13 (46) 1/19 (5) 0
Colorectal carcinoma 10.8 (6.1–15.5) 37.9 (30–45.8) 5/19 (26) 3/10 (30) 5/28 (18) 1
Otherb 8.3 (6–10.6) 32.8 (18.7–46.9) 6/15 (40) 3/6 (50) 6/26 (23) 1
All tumour types 10.1 (7.4–12.8) 37.7 (31.1–44.3) 30/74 (41) 21/44 (48) 24/111 (22) 5
Evaluable patients 122 122 74 44 111 111
P values (between groups)c <0.001 <0.001 0.098 0.494 0.022 NA
REILD radioembolization-induced liver disease
a Response includes complete response and partial response by RECIST or mRECIST, as described in the text
b Tumour cell types in this group are listed in Table 1 footnote a
c Log-rank test for survival comparison between groups; nonparametric chi-squared test for response and toxicity comparison between groups
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Treatment-related adverse events were usually mild, ex-
pected, and limited to grade 1/2 toxicity such as nausea, ab-
dominal discomfort and fatigue. Laboratory values changed as
expected (Supplementary Fig. 1). Grade 3/4 toxicity occurred
in 24 patients, most of whom had preexisting grade 1/2 toxic-
ity. Grade 4 toxicity included increases in bilirubin (two pa-
tients) and aspartate aminotransferase (AST, one patient). Ab-
solute grade 3/4 toxicity was related to tumour cell type (with
a 46 % incidence among those with HCC; P=0.022), liver
cirrhosis (P=0.002), baseline AST (P=0.002), and alanine
aminotransferase (ALT, P=0.004). However, DFL-TOT was
the strongest (P=0.010) and most comprehensive dosimetry
parameter associated with an increase in toxicity grade (Sup-
plementary Table 2 and Fig. 5). Other parameters associated
with an increase in toxicity grade included percent liver in-
volvement (P=0.038), baseline performance status (P=
0.017), and prior liver resection (P=0.020).
RE-induced liver disease (REILD), defined as liver failure,
hyperbilirubinaemia and ascites in the absence of tumour pro-
gression, occurred in five patients (4.5 %). DFL-TOTwas asso-
ciated with REILD (P=0.011). In addition, pretreatment AST
(P=0.006) and ALT (P=0.035), performance status (P=
0.038), and previous RE (P=0.031) were also associated with
REILD. Interestingly, three of the five patients had received
previous radiation therapy to the liver, either RE or external
beam radiation therapy (EBRT). The median DFL-TOT in pa-
tients with REILD was 41.2 Gy, compared to 27.9 Gy in the
other patients (P=0.011). However, corrected for previous
radiation exposure calculated by dose–volume histogram
(DVH) analysis [21], the cumulative DFL-TOT was 64.8 Gy
versus 27.9 Gy (P=0.009). Five of 13 patients (38.5 %) with
cumulative DFL-TOT >60 Gy had REILD (P<0.001). None
had progressive disease during follow-up (partial response in
three patients, stable disease in one patient, no imaging in one
patient with biopsy-proven venoocclusive disease), but medi-
an survival in these five patients was only 84 days.
The calculatedDT/DFL-TOT ratio, analogous to a physiolog-
ical tumour to normal (T/N) ratio, was <1 in 41 of the 122
patients (33.6 %). This was encountered significantly more
frequent in patients with secondary malignancy (33 of the 41
patients; P=0.009), often in patients with large overlap areas
that were positive for both TcMAA and TcSC. In contrast to
anatomical segmentation methods these overlapping areas
were included in the normal liver segment, which leads to
generally lower T/N ratios. Efficacy and toxicity parameters
Fig. 3 Kaplan-Meier survival curves for patients with an objective
response at 3 months (upper dotted line), patients without response
(lower dashed line), and all patients (middle solid line). Median survival
in responders was 36 months versus only 8.7 months in nonresponders
(P=0.003); stratified according to tumour cell type, this was still
significant (P=0.011)
Fig. 4 Kaplan-Meier survival curves for patients with hepatocellular
carcinoma (short dashes), cholangiocarcinoma (lower solid line),
metastatic neuroendocrine carcinoma (upper solid line), metastatic
colorectal carcinoma (long dashes), and miscellaneous metastatic
malignancies (dotted line)
Fig. 5 Maximum change in toxicity grade from baseline during follow-
up was significantly associated with the radiation absorbed dose to
functional liver tissue (DFL-TOT). Medians, and first and third quartiles
are indicated by the boxes (central line, and lower and upper border,
respectively), and minimum and maximum by the T-bars (circles
outliers, >1.5 times interquartile range; asterisks extreme outliers, >3
times interquartile range)
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were not found to be associated withDT/DFL-TOT <1. DT/DFL-
TOT depended on tumour cell type (Table 2), but was not
correlated with response at 3 and 6 months, toxicity, toxicity
grade increase, or REILD.
Of the 122 patients, 24 were treated with glass micro-
spheres (22 with HCC). Compared to patients treated with
resin microspheres (4 of 98 with HCC), patients treated with
glass microspheres had a statistically significant worse base-
line ECOG performance status and liver function with 75 %
known to have liver cirrhosis versus 4 % (P<0.001). They
were treated with higher activities, which resulted in higher
DT and DFL-TOT. Response rates at 3 months (64 % versus
35 %; P=0.069) and 6 months (78 % versus 40 %; P=
0.064) showed a trend in favour of glass microspheres, but
survival showed no difference (heavily biased by HCC). Re-
sponse at 3 months was associated with prolonged survival in
both groups (median 8.8 versus 39.1 months for resin, and 6.5
versus 19.8 months for glass; P=0.005). With regard to tox-
icity, worse baseline characteristics and higher DFL-TOT after
treatment with glass microspheres did not result in any asso-
ciation between glass microspheres and increased toxicity,
perhaps also because fewer patients receivedwhole-liver treat-
ment compared to those treated with resin microspheres (42 %
versus 89 %; P<0.001). Microsphere type (i.e. resin or glass)
was included as a parameter in the multivariate analysis, but
was not independently associatedwith efficacy or toxicity (see
above). Liver cirrhosis was associated with worse baseline
laboratory values, but did not result in increased toxicity per
se (being associated with absolute toxicity grade, but not with
changes in toxicity grade). As expected, patients with cirrho-
sis did have a worse survival than noncirrhotic patients (me-
dian 5.2 versus 10.8 months; P=0.033).
Discussion
Fusion TcMAA/TcSC SPECT imaging enables physiological
partitioning of the liver for intrahepatic RE dosimetry. It al-
lows calculation of the absorbed dose to the tumour and to the
functional liver parenchyma, even in patients with extensive
infiltrative and/or multifocal disease in whom anatomical
imaging-based partitioning is not feasible [1]. Across a large
variety of primary and metastatic liver tumours, we found that
tumour dose DT was correlated with objective response and
overall survival, and functional liver dose DFL-TOTwas corre-
lated with toxicity. This study clearly confirmed dose–re-
sponse relationships in a large heterogeneous cohort of pa-
tients typical of the population treated by RE.
Previous partitioning methods based on morphological an-
atomical imaging have been applied on patients with limited
disease [22, 23]. Garin et al. segmented the liver on TcMAA
SPECT/CT images by semiautomatic generation of a volume
of interest over the tumour on the SPECT images using an
isocontour method to match the tumour on the CT images.
In a preliminary report in 36 HCC patients they showed that
a threshold DT value of 205 Gy was predictive of response
[10]. These findings were confirmed in the extended cohort of
71 patients. Dosimetry enabled treatment intensification with
favourable clinical outcome in selected patients, especially in
patients with large tumours and portal vein thrombosis [24].
Mazzaferro et al. also found a correlation between DT and
response in 52 HCC patients, albeit at a higher threshold value
of 500 Gy using manual delineation of the tumour [25]. A
maximum safety threshold for normal liver parenchyma of
70Gywas advocated based on these data [26]. Although prom-
ising, anatomical partitioning is limited in clinical practice,
mainly because the presence of extensive or diffusemalignancy
is associated with substantial error. Also, these methods do not
adequately account for the compartment that contains both tu-
mour and functional liver directly surrounding the tumour.
In our study,DTwas also correlated with response and with
survival. In addition, toxicity was associated with the func-
tional liver dose DFL-TOT, a finding consistent with existing
understanding of radiation hepatotoxicity [27]. Patients with
REILD had a significantly higher DFL-TOT, often due to pre-
vious hepatic radiation exposure. Prior EBRT, as well as prior
RE treatment of the same target volume, is known to increase
RE toxicity [21, 28]. When DVH analysis and voxel-based
fusion SPECT dosimetry were applied to our cohort, we found
that cumulative DFL-TOTwas above 60 Gy in all patients with
REILD. The probability of REILD was further increased by
poor performance status and poor liver function at baseline.
The volume of the unirradiated part of the functional liver
(VFL-UN) proved to be associated with toxicity grade change
and REILD, and with survival. This mirrors the surgical tenet
that sufficient functional liver must be preserved for a better
outcome after resection. A future liver remnant (FLR) fraction
larger than 20 – 30 % is recommended in patients with a
normal liver, whereas a remnant of >40 % is recommended
in patients with cirrhosis [29]. The surgical concept of FLR
could be adapted for application to RE, with thresholds to be
defined for both the minimum volume of and the maximum
dose to ‘unirradiated functional liver’.
Our ratio DT/DFL-TOT is distinctly different from the com-
monly cited T/N ratio. Our physiological definition of func-
tional liver assigns marginal tissue to the ’normal’ compart-
ment, which probably includes hypervascular rims and ill-
defined tumours interspersed with functional parenchyma. In
contrast, the more commonly used T/N ratio is based on ana-
tomical segmentation, where ‘T’ probably includes some
functional liver surrounding the tumour. Assigning these irra-
diated areas to ‘T’will increase the T/N ratio in comparison to
our physiological DT/DFL-TOT. Including the overlap area in
DFL-TOT resulted in more accurate prediction of toxicity as
would be expected from the scintigraphic characteristics.
Some investigators have advocated using the ratio to guide
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patient selection [30, 31], finding that the FDG PET response
in mCRC lesions can be predicted using a cut-off T/N ratio of
1 [30]. However, this remains controversial, since another
study in 58mCRC patients found no correlation with response
[32]. ‘T’ and ‘N’ compartments were defined by morpholog-
ical imaging only, which may have contributed to the lack of
correlation. Our method using physiological characterization
showed that the ratio DT/DFL-TOT was not correlated with ef-
ficacy or toxicity; rather, the actual values of DT and DFL-TOT
were more predictive.
Based on the results of this study, some preliminary sug-
gestions may be provided for prospective use of dual-tracer
SPECT dosimetry. None of the patients with REILD had a
DFL-TOT <30 Gy from RE or a cumulative DFL-TOT <60 Gy.
This suggests an alternative strategy for dose prescription: to
adjust the administered activity to keep DFL-TOT below a risk
threshold. Surprisingly, a cumulative DFL-TOT of 30 – 60 Gy
appeared to be well tolerated, but the risk of REILD ifDFL-TOT
exceeded 60 Gy was 38 %. A DT >32.7 Gy led to a 50 %
objective response rate, irrespective of tumour cell type. It
seems reasonable to aim for DT >32.7 Gy if cumulative DFL-
TOT can be kept below 30 Gy. Under this proposal, of the 122
patients in our cohort, administered activity could potentially
have been increased in 65 patients (53 %). Thirteen patients
(11 %), including the five with REILD, would have required
activity reduction to keepDFL-TOT below 30 Gy. This strategy
will need to be validated using a prospective protocol.
Threshold DT and DFL-TOT may prove to be different be-
tween glass and resin microspheres. These products differ in
activities prescribed, specific activity, embolization effect, and
often proportion of the liver treated. Dose–effect relationships
for both efficacy and toxicity are influenced by these differ-
ences. Dose–effect relationships probably also differ for each
tumour cell type and for different baseline liver function sta-
tuses. With additional experience, thresholds should be de-
fined tailored to different tumour cell types and product used.
However, even with our amalgamated heterogeneous cohort,
significant dose–response relationships were identified.
The limitations of this study include its retrospective design
and imperfect toxicity and efficacy analysis. Strong endpoints,
such as REILD, had a low incidence, while weaker endpoints,
such as grade 3/4 toxicity, were heavily confounded by pretreat-
ment morbidity, tumour cell type, and disease progression. Re-
sponse evaluation was confounded by the premature death of
patients who were censored, resulting in biased response rates.
The reported absolute absorbed doses in tumorous and
nontumorous tissue should be considered with care, since ab-
solute SPECT quantification in the current study was prone to
error due to the use of older technology. Although clinical
SPECT can be quantitative with errors of less than 10 %, it
requires careful set-up and calibration, as well as state-of-the-
art SPECT/CT systems and iterative reconstruction software
able to accurately model the imaging physics, and to
compensate for image-degrading factors (i.e. attenuation, scat-
ter and partial volume) [33].
Work in progress includes optimization of image analysis
using SPECT/CT and CT-based attenuation correction (not
available at the time), dose-point kernel algorithms, and
SPECT-based DVH analysis. Automatic threshold-based seg-
mentation will be refined based on these techniques, to find a
balance between the threshold used and the segmented vol-
ume. Future studies will focus on defining absorbed dose
threshold values for fusion dual-tracer SPECT dosimetry in
a prospective controlled setting.
Conclusion
Fusion TcMAA/TcSC SPECT imaging is a true physiology-
based functional imaging tool that reveals dose–response re-
lationships for hepatic RE. Absorbed doses in tumours and in
functional liver tissue correlate with response, survival and
toxicity in a heterogeneous population. This method may be
useful for individualized treatment planning.
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